12:00 AM
 | 
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ixmyelocel-T: Phase II suspended enrollment

Aastrom suspended enrollment and patient treatment in the open-label, U.S. Phase II IMPACT-DCM trial of CRCs to treat DCM after a patient died at home following treatment in the trial. The cause of death has not yet been determined. The company said FDA placed the trial on temporary hold pending an investigation. In February, FDA...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >